Amneal Pharmaceuticals Inc
F:2DT
Amneal Pharmaceuticals Inc
Inventory
Amneal Pharmaceuticals Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Amneal Pharmaceuticals Inc
F:2DT
|
Inventory
$614.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
17%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Inventory
$14.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Inventory
$2.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Pfizer Inc
NYSE:PFE
|
Inventory
$10.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Inventory
$6.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Inventory
$13.7B
|
CAGR 3-Years
47%
|
CAGR 5-Years
28%
|
CAGR 10-Years
15%
|
|
Amneal Pharmaceuticals Inc
Glance View
Amneal Pharmaceuticals Inc., birthed from the vision of two brothers, Chirag and Chintu Patel, stands today as a formidable entity in the generic and specialty pharmaceutical sector. Emerging from its modest beginnings in 2002 in Paterson, New Jersey, Amneal has embarked on a remarkable journey of growth and innovation. The company is best known for its strong portfolio of affordable generic medicines, which span a broad range of therapeutic areas. This ensures that they provide essential medications at more accessible prices, thus fulfilling a critical role in healthcare by making necessary treatments available to wider demographics. The company leverages vertical integration and cutting-edge manufacturing facilities to maintain high efficiency, allowing it to consistently produce and distribute pharmaceuticals on a global scale. Beyond generics, Amneal has diversified its operations to include complex drug delivery systems and specialty pharmaceuticals, carving out a niche in the more profitable segments of the pharmaceutical industry. By investing in research and development, the company continues to innovate, focusing particularly on high-barrier segments such as biosimilars and injectable medications. This strategic pivot not only enhances the company’s product offerings but also positions it more robustly against market volatilities. Amneal generates revenue by manufacturing and distributing its extensive product portfolio through partnerships with both retailers and health care facilities, ensuring a steady flow of sales. The company’s dual approach of maintaining a strong base in generics while exploring specialty and complex products shines a beacon on its strategic flexibility and its commitment to sustainable growth in the ever-evolving pharmaceutical landscape.
See Also
What is Amneal Pharmaceuticals Inc's Inventory?
Inventory
614.5m
USD
Based on the financial report for Sep 30, 2025, Amneal Pharmaceuticals Inc's Inventory amounts to 614.5m USD.
What is Amneal Pharmaceuticals Inc's Inventory growth rate?
Inventory CAGR 10Y
17%
Over the last year, the Inventory growth was 3%. The average annual Inventory growth rates for Amneal Pharmaceuticals Inc have been 4% over the past three years , 5% over the past five years , and 17% over the past ten years .